Multiple analysts have issued price targets for $MNOV recently. We have seen 2 analysts offer price targets for $MNOV in the last 6 months, with a median target of $7.0.
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
Oct 30, 2025
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces the publication of a new research article in the peer-reviewed Journal of Atherosclerosis and Thrombosis, the official journal of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Disease.
The study, titled, “Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis,” is the result of a collaboration effort between MediciNova and a leading Japanese academic research group specializing in lipid and cholesterol metabolism. The research demonstrated that MN-002, the major metabolite of Company’s investigational compound MN-001 (tipelukast), significantly enhanced cholesterol efflux in macrophages by upregulating key transport proteins ABCA1 and ABCG. These findings suggest a novel mechanism of action and potential therapeutic strategy for atherosclerosis and other metabolic disorders.
“This collaborative research provides the mechanistic insight into how MN-001 and its metabolite MN-002 may influence cholesterol and lipid metabolism. We are pleased to see these findings published in a prestigious journal and remain committed to exploring the full therapeutic potential of MN-001, an orally available small molecule with anti-inflammatory and anti-fibrotic properties. We look forward to further clinical investigation in metabolic disease, including dyslipidemia and Type 2 diabetes,” said Yuichi Iwaki, M.D., Ph.D., MediciNova President and Chief Executive Officer.
Previous clinical studies have shown that MN-001 improved serum lipid profiles in patients with Non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, with particularly notable effects in patients with type 2 diabetes (DM). MediciNova is currently conducting a randomized, placebo-control, double-blind Phase 2 study in hypertriglyceridemia, Type 2 DM and NAFLD patients, with enrollment nearing completion.
About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
Market Data 
Markets 
AI
